Market Insights Health Medical Technology

In Vitro Diagnostics - North America

North America

The In Vitro Diagnostics market market in North America is anticipated to achieve a revenue milestone of US$33.29bn by 2024.
It is projected to exhibit a steady annual growth rate (CAGR 2024-2029) of 2.38%, leading to a market volume of US$37.45bn by 2029.
In terms of global comparison, the United States is expected to generate the highest revenue, amounting to US$30,100.00m in 2024.
In North America's In Vitro Diagnostics market, there is a growing demand for advanced molecular testing technologies.

Key regions: China, France, Japan, Netherlands, Italy

Market

Region

Region comparison

Currency

Analyst Opinion

The In Vitro Diagnostics market in North America is experiencing significant growth and development due to several key factors. Customer preferences for advanced diagnostic technologies, increasing prevalence of chronic diseases, and favorable government regulations are driving the market forward. Additionally, local special circumstances, such as the high healthcare expenditure and the presence of major market players, contribute to the growth of the In Vitro Diagnostics market in North America. Customer preferences in North America are shifting towards advanced diagnostic technologies that provide accurate and timely results. Patients and healthcare providers are increasingly demanding diagnostic tests that can detect diseases at an early stage, leading to better treatment outcomes. This has fueled the demand for molecular diagnostics, point-of-care testing, and other innovative diagnostic solutions in the region. The prevalence of chronic diseases, such as cardiovascular diseases, cancer, and diabetes, is on the rise in North America. This has created a need for effective diagnostic tools that can aid in early detection and monitoring of these diseases. In Vitro Diagnostics play a crucial role in the management of chronic diseases by providing valuable insights into the patient's condition and guiding treatment decisions. As a result, the demand for In Vitro Diagnostics is expected to grow significantly in the coming years. Government regulations in North America are supportive of the In Vitro Diagnostics market. Regulatory bodies such as the FDA in the United States have implemented streamlined approval processes for diagnostic tests, enabling faster market entry for manufacturers. This has encouraged innovation and investment in the sector, leading to the development of new and improved diagnostic technologies. Local special circumstances in North America, such as the high healthcare expenditure, contribute to the growth of the In Vitro Diagnostics market. The region has a well-established healthcare system with a focus on advanced medical technologies. This creates a favorable environment for the adoption of In Vitro Diagnostics, as healthcare providers have the resources and infrastructure to invest in these technologies. North America is home to several major market players in the In Vitro Diagnostics industry. These companies have a strong presence in the region and are actively involved in research and development activities. Their expertise and market influence drive innovation and competition, leading to the introduction of new and improved diagnostic solutions. Underlying macroeconomic factors, such as the growing aging population and increasing healthcare expenditure, also contribute to the development of the In Vitro Diagnostics market in North America. The aging population is more prone to chronic diseases, creating a higher demand for diagnostic tests. Additionally, the rising healthcare expenditure indicates a greater investment in healthcare infrastructure and technologies, including In Vitro Diagnostics. Overall, the In Vitro Diagnostics market in North America is witnessing significant growth and development due to customer preferences for advanced diagnostic technologies, increasing prevalence of chronic diseases, favorable government regulations, local special circumstances, and underlying macroeconomic factors. These factors are expected to continue driving the market forward in the coming years.

Methodology

Data coverage:

Data encompasses B2B, B2G, and B2C spend. Figures are based on medical devices and IVD revenues allocated to the country where the money is spent at manufacturer price levels excluding VAT.

Modeling approach / Market size:

Modeling employs a top-down approach with a bottom-up validation, using financial information of the key players by market. Market sizes are determined by a top-down approach, based on a specific rationale for each market market and allocated to the covered countries according to the global market shares. As a basis for evaluating markets, we use relevant key market indicators and data from country-specific associations, such as healthcare expenditure per capita, health risk factors, healthcare system, and regulations concerning medical products. Next, we use further relevant key market indicators and data from country-specific associations, such as healthcare expenditure per capita, health risk factors, healthcare payer system, and regulations concerning medical products. This data helps us estimate the market size for each country individually.

Forecasts:

In our forecasts, we apply diverse forecasting techniques. The selection of forecasting techniques is based on the behavior of the particular market. For example, forecasts are based on historical developments, current trends, and key market indicators.

Additional notes:

Data is modeled in US$ using current exchange rates. The market is updated twice per year in case market dynamics change. The impact of the COVID-19 pandemic is considered at a country-specific level.